SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is rallying behind the project with intense conviction, emphasizing long-term 'bagworking' and the creation of OG-style rage comics to drive mindshare. Investors are actively pushing to secure a top market position while warning against copycat tickers and urging others to join their grassroots effort before a potential breakout.

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The Melania Crypto token is actively being labeled by the community as a major pump-and-dump scheme, with discussions centering on the massive losses sustained by retail investors compared to the significant profits reportedly realized by insiders and organizers. Many users are using the symbol as a venue to vent political frustrations and share concerns about the perceived grifting tactics associated with the Trump family's various crypto and media ventures.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following the publication of positive Phase 3 VIKTORIA-1 trial data, which demonstrated significant survival benefits for its investigational breast cancer drug, gedatolisib. Investors are actively discussing the potential for an accelerated FDA approval timeline, the strategic implications of a recent capital raise, and the stock's long-term value as a potential first-in-class standard of care.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending as investors closely monitor its role in the AI-driven data center and optical packaging sector, with community sentiment divided between excitement over long-term growth and caution regarding valuation and potential supply chain shifts. Discussion is heavily focused on the company's recent earnings performance, its strategic importance as a manufacturer for major tech partners, and its ability to sustain momentum amid sector volatility.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is gaining institutional momentum ahead of its upcoming earnings as investors rotate out of technology and into resilient healthcare names, while the company leverages a robust portfolio of mature drugs and late-stage pipeline assets to navigate competitive pricing pressures. Market participants are closely watching the company's capital allocation strategy and manufacturing expansion efforts, which are being bolstered by favorable policy developments and a strengthening competitive position in the cardiovascular and inflammatory disease markets.

Ecopetrol SA engages in the exploration, development, and production of crude oil and natural gas. It operates through the following segments: Exploration and Production, Transportation and Logistics, and Refining and Petrochemicals. The Exploration and Production segment deals with oil and gas exploration and production activities. The Transportation and Logistics segment comprises of pipelines and other transportation activities. The Refining and Petrochemicals segment involves in refining activities and its products include motor fuels, fuel oils, and petrochemicals. The company was founded in 1948 and is headquartered in Bogota, Colombia.

Ecopetrol SA - ADR

Ecopetrol SA

Ecopetrol is trending as investors weigh its potential as an undervalued energy play with a strong dividend yield against ongoing geopolitical risks in Colombia and shifting global oil market dynamics. The community is actively debating the stock's long-term outlook, focusing on the company's operational resilience and the impact of political developments on its future growth.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Investors are closely watching the iPath S&P 500 VIX Short-Term Futures ETN (VXX) as market participants debate whether extreme volatility-shorting behavior signals a major market peak or continued complacency. Community discussion is currently fixated on whether the recent compression in volatility indices, coupled with macroeconomic uncertainty, is setting the stage for a significant capitulatory event or another aggressive melt-up.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor attention due to speculation regarding its short-squeeze potential and optimism surrounding its strategic AI partnerships. Community discussions are heavily focused on the stock's low float and aggressive roadmap, leading to polarized debates over whether the momentum represents a long-term growth opportunity or a volatile trading setup.

Direxion Shares ETF Trust - Direxion Daily Energy Bull 2X ETF

Direxion Daily Energy Bull 2X Shares

The Direxion Daily Energy Bull 2X Shares (ERX) is experiencing significant attention as traders and analysts debate the sector's outlook amid ongoing geopolitical tensions, supply fluctuations, and shifting sentiment regarding energy demand. Investors are actively tracking institutional flow and sector gauge signals to navigate the fund's volatility while discussing the potential impact of global macroeconomic policy on crude oil related investments.

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Puma Biotechnology is trending as investors digest its recent NASDAQ Biotechnology Index inclusion and significant developments in its intellectual property lawsuit against AstraZeneca, fueling intense community discussion around its perceived undervaluation, potential for a substantial buyout, and upcoming clinical trial data for its oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should Cresco Stock Be in Your Portfolio Post Q4 Earnings?

CRLBF faces US pricing pressure despite a Q4 sales beat and a strategic entry into Germany's cannabis market, raising questions about near-term upside.

Cresco Labs Inc. (CRLBF) Reports Q4 Loss, Beats Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of +14.16% and +0.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cannabis Stock VRNO Rises 40% in a Year: Time to Buy, Sell or Hold?

Verano stock has surged more than 40% in a year amid U.S. marijuana rescheduling optimism, but revenue headwinds and rising competition may keep investors cautious.

Perrigo (PRGO) Q4 Earnings Lag Estimates

Perrigo (PRGO) delivered earnings and revenue surprises of -3.75% and +0.72%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for February 9th

GPRE, CRLBF and BSET have been added to the Zacks Rank #5 (Strong Sell) List on February 9, 2026.

Should You Buy GTBIF Stock After Marijuana Reclassification Order?

Shares of Green Thumb GTBIF jump nearly 35% on a marijuana rescheduling order, but pricing pressure and weak comps cloud the stock's near-term outlook.

Tilray Brands Strengthens Domestic Lead With Strong Q1 Cannabis Growth

TLRY posts a strong quarter as Canadian cannabis revenues grow and market shares climb across key product categories.

TLRY vs. CRLBF: Which Cannabis Player Offers Greater Upside?

Tilray Brands' global expansion and strong Canadian momentum spotlight its edge as investors weigh upside against Cresco Labs' slower growth.

Cresco Labs Expands Operations Beyond U.S.: How to Play the Stock?

CRLBF's move into Germany opens a new growth path as it navigates U.S. pricing pressure and rising competition in its core market.

Cresco Labs Inc. (CRLBF) Reports Q3 Loss, Beats Revenue Estimates

Cresco Labs Inc. (CRLBF) delivered earnings and revenue surprises of -66.67% and +0.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Cresco Labs Inc. engages in cultivating medical grade cannabis, manufacturing medical products derived from cannabis cultivation, and distributing such products to medical or adult use consumers. It focuses on regulatory compliance while working to develop condition-specific strains of cannabis and non-invasive delivery methods. The company was founded by Charles Bachtel, Joseph Caltabiano, Dominic Sergi, Rob Sampson, and Brian McCormack on July 6, 1990 and is headquartered in Chicago, IL.

CRLBF
Cresco Labs Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRLBF News

CRLBFCresco Labs Inc